nodes	percent_of_prediction	percent_of_DWPC	metapath
Phentolamine—SIGMAR1—Raloxifene—breast cancer	0.314	0.602	CbGbCtD
Phentolamine—SIGMAR1—Tamoxifen—breast cancer	0.208	0.398	CbGbCtD
Phentolamine—NISCH—mammary gland—breast cancer	0.00496	0.0779	CbGeAlD
Phentolamine—NISCH—nipple—breast cancer	0.0041	0.0644	CbGeAlD
Phentolamine—SIGMAR1—mammary gland—breast cancer	0.00289	0.0453	CbGeAlD
Phentolamine—NISCH—Paclitaxel—Docetaxel—breast cancer	0.00287	0.358	CbGdCrCtD
Phentolamine—SIGMAR1—nipple—breast cancer	0.00239	0.0375	CbGeAlD
Phentolamine—ADRA1D—epithelium—breast cancer	0.00231	0.0362	CbGeAlD
Phentolamine—NISCH—uterus—breast cancer	0.00228	0.0358	CbGeAlD
Phentolamine—NISCH—pituitary gland—breast cancer	0.00224	0.0352	CbGeAlD
Phentolamine—NISCH—adipose tissue—breast cancer	0.00223	0.035	CbGeAlD
Phentolamine—NISCH—adrenal gland—breast cancer	0.002	0.0314	CbGeAlD
Phentolamine—NISCH—Vincristine—Vinorelbine—breast cancer	0.00197	0.246	CbGdCrCtD
Phentolamine—NISCH—bone marrow—breast cancer	0.00194	0.0304	CbGeAlD
Phentolamine—ADRA2C—nipple—breast cancer	0.00187	0.0294	CbGeAlD
Phentolamine—NISCH—female gonad—breast cancer	0.00187	0.0293	CbGeAlD
Phentolamine—ADRA1D—female reproductive system—breast cancer	0.00171	0.0269	CbGeAlD
Phentolamine—NISCH—Vinblastine—Vinorelbine—breast cancer	0.00159	0.198	CbGdCrCtD
Phentolamine—NISCH—Vincristine—Vinblastine—breast cancer	0.00158	0.197	CbGdCrCtD
Phentolamine—ADRA2A—nipple—breast cancer	0.0015	0.0235	CbGeAlD
Phentolamine—ADRA1D—endocrine gland—breast cancer	0.00145	0.0228	CbGeAlD
Phentolamine—SIGMAR1—endometrium—breast cancer	0.00144	0.0226	CbGeAlD
Phentolamine—SIGMAR1—uterus—breast cancer	0.00133	0.0208	CbGeAlD
Phentolamine—ADRA1A—epithelium—breast cancer	0.00132	0.0208	CbGeAlD
Phentolamine—SIGMAR1—pituitary gland—breast cancer	0.0013	0.0205	CbGeAlD
Phentolamine—SIGMAR1—adipose tissue—breast cancer	0.0013	0.0204	CbGeAlD
Phentolamine—NISCH—lymph node—breast cancer	0.0012	0.0188	CbGeAlD
Phentolamine—SIGMAR1—adrenal gland—breast cancer	0.00117	0.0183	CbGeAlD
Phentolamine—ADRA2C—endometrium—breast cancer	0.00113	0.0178	CbGeAlD
Phentolamine—SIGMAR1—bone marrow—breast cancer	0.00113	0.0177	CbGeAlD
Phentolamine—SIGMAR1—female gonad—breast cancer	0.00109	0.017	CbGeAlD
Phentolamine—ADRA1A—adipose tissue—breast cancer	0.00107	0.0168	CbGeAlD
Phentolamine—ADRA2C—uterus—breast cancer	0.00104	0.0164	CbGeAlD
Phentolamine—ADRA2C—pituitary gland—breast cancer	0.00102	0.0161	CbGeAlD
Phentolamine—ADRA2C—adipose tissue—breast cancer	0.00102	0.016	CbGeAlD
Phentolamine—ADRA1A—adrenal gland—breast cancer	0.00096	0.0151	CbGeAlD
Phentolamine—ADRA2C—adrenal gland—breast cancer	0.000915	0.0144	CbGeAlD
Phentolamine—ADRA2A—endometrium—breast cancer	0.000903	0.0142	CbGeAlD
Phentolamine—ADRA2C—female gonad—breast cancer	0.000853	0.0134	CbGeAlD
Phentolamine—ADRA1A—endocrine gland—breast cancer	0.000833	0.0131	CbGeAlD
Phentolamine—ADRA2A—uterus—breast cancer	0.000832	0.0131	CbGeAlD
Phentolamine—ADRA2A—pituitary gland—breast cancer	0.000817	0.0128	CbGeAlD
Phentolamine—ADRA2A—adipose tissue—breast cancer	0.000814	0.0128	CbGeAlD
Phentolamine—ADRA2A—female reproductive system—breast cancer	0.000748	0.0117	CbGeAlD
Phentolamine—ADRA2A—adrenal gland—breast cancer	0.00073	0.0115	CbGeAlD
Phentolamine—SIGMAR1—lymph node—breast cancer	0.000699	0.011	CbGeAlD
Phentolamine—ADRA2A—female gonad—breast cancer	0.000681	0.0107	CbGeAlD
Phentolamine—ADRA2A—endocrine gland—breast cancer	0.000633	0.00994	CbGeAlD
Phentolamine—ADRA2C—lymph node—breast cancer	0.000549	0.00861	CbGeAlD
Phentolamine—ADRA2A—lymph node—breast cancer	0.000438	0.00687	CbGeAlD
Phentolamine—Pruritus—Chlorambucil—breast cancer	0.000423	0.00136	CcSEcCtD
Phentolamine—Abdominal pain—Tamoxifen—breast cancer	0.000421	0.00136	CcSEcCtD
Phentolamine—Gastrointestinal pain—Goserelin—breast cancer	0.000416	0.00134	CcSEcCtD
Phentolamine—Diarrhoea—Chlorambucil—breast cancer	0.000409	0.00132	CcSEcCtD
Phentolamine—Paraesthesia—Vinorelbine—breast cancer	0.000409	0.00132	CcSEcCtD
Phentolamine—Abdominal pain—Goserelin—breast cancer	0.000402	0.00129	CcSEcCtD
Phentolamine—Acute coronary syndrome—Docetaxel—breast cancer	0.000402	0.00129	CcSEcCtD
Phentolamine—Cardiac disorder—Paclitaxel—breast cancer	0.0004	0.00129	CcSEcCtD
Phentolamine—Flushing—Paclitaxel—breast cancer	0.0004	0.00129	CcSEcCtD
Phentolamine—Myocardial infarction—Docetaxel—breast cancer	0.000399	0.00129	CcSEcCtD
Phentolamine—Hypertension—Mitoxantrone—breast cancer	0.000398	0.00128	CcSEcCtD
Phentolamine—Hypertension—Irinotecan—breast cancer	0.000398	0.00128	CcSEcCtD
Phentolamine—Asthenia—Vinblastine—breast cancer	0.000393	0.00127	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Vinorelbine—breast cancer	0.000393	0.00127	CcSEcCtD
Phentolamine—Chest pain—Mitoxantrone—breast cancer	0.000392	0.00126	CcSEcCtD
Phentolamine—Angiopathy—Paclitaxel—breast cancer	0.000391	0.00126	CcSEcCtD
Phentolamine—Paraesthesia—Thiotepa—breast cancer	0.000391	0.00126	CcSEcCtD
Phentolamine—Pain—Vinorelbine—breast cancer	0.00039	0.00125	CcSEcCtD
Phentolamine—Mediastinal disorder—Paclitaxel—breast cancer	0.000389	0.00125	CcSEcCtD
Phentolamine—Acute coronary syndrome—Capecitabine—breast cancer	0.000389	0.00125	CcSEcCtD
Phentolamine—Hypertension—Gemcitabine—breast cancer	0.000387	0.00125	CcSEcCtD
Phentolamine—Myocardial infarction—Capecitabine—breast cancer	0.000387	0.00124	CcSEcCtD
Phentolamine—Arrhythmia—Paclitaxel—breast cancer	0.000385	0.00124	CcSEcCtD
Phentolamine—Asthenia—Tamoxifen—breast cancer	0.000382	0.00123	CcSEcCtD
Phentolamine—Chest pain—Gemcitabine—breast cancer	0.000382	0.00123	CcSEcCtD
Phentolamine—Vomiting—Chlorambucil—breast cancer	0.00038	0.00122	CcSEcCtD
Phentolamine—Pruritus—Tamoxifen—breast cancer	0.000377	0.00121	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Thiotepa—breast cancer	0.000376	0.00121	CcSEcCtD
Phentolamine—Chest pain—Fluorouracil—breast cancer	0.000375	0.00121	CcSEcCtD
Phentolamine—Diarrhoea—Vinblastine—breast cancer	0.000375	0.00121	CcSEcCtD
Phentolamine—Asthenia—Melphalan—breast cancer	0.000374	0.0012	CcSEcCtD
Phentolamine—Gastrointestinal pain—Vinorelbine—breast cancer	0.000373	0.0012	CcSEcCtD
Phentolamine—Pain—Thiotepa—breast cancer	0.000372	0.0012	CcSEcCtD
Phentolamine—Pruritus—Melphalan—breast cancer	0.000369	0.00119	CcSEcCtD
Phentolamine—Nervous system disorder—Irinotecan—breast cancer	0.000369	0.00119	CcSEcCtD
Phentolamine—Tachycardia—Mitoxantrone—breast cancer	0.000367	0.00118	CcSEcCtD
Phentolamine—Asthenia—Goserelin—breast cancer	0.000365	0.00117	CcSEcCtD
Phentolamine—Diarrhoea—Tamoxifen—breast cancer	0.000364	0.00117	CcSEcCtD
Phentolamine—Dizziness—Vinblastine—breast cancer	0.000363	0.00117	CcSEcCtD
Phentolamine—Bradycardia—Capecitabine—breast cancer	0.00036	0.00116	CcSEcCtD
Phentolamine—Abdominal pain—Vinorelbine—breast cancer	0.00036	0.00116	CcSEcCtD
Phentolamine—Pruritus—Goserelin—breast cancer	0.00036	0.00116	CcSEcCtD
Phentolamine—Nervous system disorder—Gemcitabine—breast cancer	0.000359	0.00116	CcSEcCtD
Phentolamine—Diarrhoea—Melphalan—breast cancer	0.000357	0.00115	CcSEcCtD
Phentolamine—Gastrointestinal pain—Thiotepa—breast cancer	0.000356	0.00115	CcSEcCtD
Phentolamine—Nausea—Chlorambucil—breast cancer	0.000355	0.00114	CcSEcCtD
Phentolamine—Nervous system disorder—Fluorouracil—breast cancer	0.000353	0.00114	CcSEcCtD
Phentolamine—Dizziness—Tamoxifen—breast cancer	0.000352	0.00113	CcSEcCtD
Phentolamine—Tachycardia—Fluorouracil—breast cancer	0.000351	0.00113	CcSEcCtD
Phentolamine—Hypotension—Mitoxantrone—breast cancer	0.000351	0.00113	CcSEcCtD
Phentolamine—Hypotension—Irinotecan—breast cancer	0.000351	0.00113	CcSEcCtD
Phentolamine—Vomiting—Vinblastine—breast cancer	0.000349	0.00112	CcSEcCtD
Phentolamine—Diarrhoea—Goserelin—breast cancer	0.000348	0.00112	CcSEcCtD
Phentolamine—Abdominal pain—Thiotepa—breast cancer	0.000344	0.00111	CcSEcCtD
Phentolamine—Headache—Vinblastine—breast cancer	0.000343	0.00111	CcSEcCtD
Phentolamine—Hypotension—Gemcitabine—breast cancer	0.000342	0.0011	CcSEcCtD
Phentolamine—Flushing—Docetaxel—breast cancer	0.000339	0.00109	CcSEcCtD
Phentolamine—Cardiac disorder—Docetaxel—breast cancer	0.000339	0.00109	CcSEcCtD
Phentolamine—Vomiting—Tamoxifen—breast cancer	0.000339	0.00109	CcSEcCtD
Phentolamine—Paraesthesia—Irinotecan—breast cancer	0.000337	0.00109	CcSEcCtD
Phentolamine—Paraesthesia—Mitoxantrone—breast cancer	0.000337	0.00109	CcSEcCtD
Phentolamine—Dizziness—Goserelin—breast cancer	0.000336	0.00108	CcSEcCtD
Phentolamine—Hypotension—Fluorouracil—breast cancer	0.000336	0.00108	CcSEcCtD
Phentolamine—Headache—Tamoxifen—breast cancer	0.000334	0.00107	CcSEcCtD
Phentolamine—Angiopathy—Docetaxel—breast cancer	0.000332	0.00107	CcSEcCtD
Phentolamine—Vomiting—Melphalan—breast cancer	0.000332	0.00107	CcSEcCtD
Phentolamine—Mediastinal disorder—Docetaxel—breast cancer	0.00033	0.00106	CcSEcCtD
Phentolamine—Paraesthesia—Gemcitabine—breast cancer	0.000329	0.00106	CcSEcCtD
Phentolamine—Cardiac disorder—Capecitabine—breast cancer	0.000329	0.00106	CcSEcCtD
Phentolamine—Flushing—Capecitabine—breast cancer	0.000329	0.00106	CcSEcCtD
Phentolamine—Asthenia—Vinorelbine—breast cancer	0.000327	0.00105	CcSEcCtD
Phentolamine—Arrhythmia—Docetaxel—breast cancer	0.000327	0.00105	CcSEcCtD
Phentolamine—Nausea—Vinblastine—breast cancer	0.000326	0.00105	CcSEcCtD
Phentolamine—Abdominal pain upper—Epirubicin—breast cancer	0.000326	0.00105	CcSEcCtD
Phentolamine—Orthostatic hypotension—Epirubicin—breast cancer	0.000326	0.00105	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Irinotecan—breast cancer	0.000324	0.00104	CcSEcCtD
Phentolamine—Hypertension—Paclitaxel—breast cancer	0.000324	0.00104	CcSEcCtD
Phentolamine—Vomiting—Goserelin—breast cancer	0.000323	0.00104	CcSEcCtD
Phentolamine—Paraesthesia—Fluorouracil—breast cancer	0.000323	0.00104	CcSEcCtD
Phentolamine—Pruritus—Vinorelbine—breast cancer	0.000322	0.00104	CcSEcCtD
Phentolamine—Pain—Mitoxantrone—breast cancer	0.000321	0.00103	CcSEcCtD
Phentolamine—Pain—Irinotecan—breast cancer	0.000321	0.00103	CcSEcCtD
Phentolamine—Angiopathy—Capecitabine—breast cancer	0.000321	0.00103	CcSEcCtD
Phentolamine—Chest pain—Paclitaxel—breast cancer	0.00032	0.00103	CcSEcCtD
Phentolamine—Mediastinal disorder—Capecitabine—breast cancer	0.000319	0.00103	CcSEcCtD
Phentolamine—Headache—Goserelin—breast cancer	0.000319	0.00103	CcSEcCtD
Phentolamine—Nausea—Tamoxifen—breast cancer	0.000316	0.00102	CcSEcCtD
Phentolamine—Arrhythmia—Capecitabine—breast cancer	0.000316	0.00102	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Gemcitabine—breast cancer	0.000316	0.00102	CcSEcCtD
Phentolamine—Pain—Gemcitabine—breast cancer	0.000313	0.00101	CcSEcCtD
Phentolamine—Asthenia—Thiotepa—breast cancer	0.000312	0.001	CcSEcCtD
Phentolamine—Diarrhoea—Vinorelbine—breast cancer	0.000312	0.001	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000311	0.001	CcSEcCtD
Phentolamine—Nausea—Melphalan—breast cancer	0.00031	0.000997	CcSEcCtD
Phentolamine—Pruritus—Thiotepa—breast cancer	0.000308	0.000991	CcSEcCtD
Phentolamine—Pain—Fluorouracil—breast cancer	0.000308	0.000991	CcSEcCtD
Phentolamine—Gastrointestinal pain—Mitoxantrone—breast cancer	0.000307	0.000989	CcSEcCtD
Phentolamine—Gastrointestinal pain—Irinotecan—breast cancer	0.000307	0.000989	CcSEcCtD
Phentolamine—Nausea—Goserelin—breast cancer	0.000302	0.000973	CcSEcCtD
Phentolamine—Dizziness—Vinorelbine—breast cancer	0.000301	0.00097	CcSEcCtD
Phentolamine—Orthostatic hypotension—Doxorubicin—breast cancer	0.000301	0.00097	CcSEcCtD
Phentolamine—Abdominal pain upper—Doxorubicin—breast cancer	0.000301	0.00097	CcSEcCtD
Phentolamine—Nervous system disorder—Paclitaxel—breast cancer	0.000301	0.000967	CcSEcCtD
Phentolamine—Angina pectoris—Epirubicin—breast cancer	0.0003	0.000966	CcSEcCtD
Phentolamine—Tachycardia—Paclitaxel—breast cancer	0.000299	0.000963	CcSEcCtD
Phentolamine—Diarrhoea—Thiotepa—breast cancer	0.000298	0.000958	CcSEcCtD
Phentolamine—Abdominal pain—Mitoxantrone—breast cancer	0.000297	0.000956	CcSEcCtD
Phentolamine—Abdominal pain—Irinotecan—breast cancer	0.000297	0.000956	CcSEcCtD
Phentolamine—Vomiting—Vinorelbine—breast cancer	0.00029	0.000932	CcSEcCtD
Phentolamine—Dizziness—Thiotepa—breast cancer	0.000288	0.000926	CcSEcCtD
Phentolamine—Hypotension—Paclitaxel—breast cancer	0.000286	0.000922	CcSEcCtD
Phentolamine—Headache—Vinorelbine—breast cancer	0.000285	0.000919	CcSEcCtD
Phentolamine—Angina pectoris—Doxorubicin—breast cancer	0.000278	0.000894	CcSEcCtD
Phentolamine—Vomiting—Thiotepa—breast cancer	0.000277	0.000891	CcSEcCtD
Phentolamine—Paraesthesia—Paclitaxel—breast cancer	0.000275	0.000886	CcSEcCtD
Phentolamine—Hypertension—Docetaxel—breast cancer	0.000275	0.000885	CcSEcCtD
Phentolamine—Headache—Thiotepa—breast cancer	0.000273	0.000877	CcSEcCtD
Phentolamine—Chest pain—Docetaxel—breast cancer	0.000271	0.000872	CcSEcCtD
Phentolamine—Nausea—Vinorelbine—breast cancer	0.000271	0.000871	CcSEcCtD
Phentolamine—Asthenia—Irinotecan—breast cancer	0.00027	0.000868	CcSEcCtD
Phentolamine—Asthenia—Mitoxantrone—breast cancer	0.00027	0.000868	CcSEcCtD
Phentolamine—Hypertension—Capecitabine—breast cancer	0.000266	0.000856	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000265	0.000852	CcSEcCtD
Phentolamine—Asthenia—Gemcitabine—breast cancer	0.000263	0.000845	CcSEcCtD
Phentolamine—Chest pain—Capecitabine—breast cancer	0.000262	0.000844	CcSEcCtD
Phentolamine—Pain—Paclitaxel—breast cancer	0.000262	0.000844	CcSEcCtD
Phentolamine—Pruritus—Gemcitabine—breast cancer	0.000259	0.000834	CcSEcCtD
Phentolamine—Nausea—Thiotepa—breast cancer	0.000258	0.000832	CcSEcCtD
Phentolamine—Diarrhoea—Irinotecan—breast cancer	0.000257	0.000828	CcSEcCtD
Phentolamine—Diarrhoea—Mitoxantrone—breast cancer	0.000257	0.000828	CcSEcCtD
Phentolamine—Nervous system disorder—Docetaxel—breast cancer	0.000255	0.00082	CcSEcCtD
Phentolamine—Pruritus—Fluorouracil—breast cancer	0.000255	0.00082	CcSEcCtD
Phentolamine—Tachycardia—Docetaxel—breast cancer	0.000254	0.000816	CcSEcCtD
Phentolamine—Bradycardia—Epirubicin—breast cancer	0.000251	0.000808	CcSEcCtD
Phentolamine—Gastrointestinal pain—Paclitaxel—breast cancer	0.000251	0.000807	CcSEcCtD
Phentolamine—Diarrhoea—Gemcitabine—breast cancer	0.00025	0.000806	CcSEcCtD
Phentolamine—Dizziness—Irinotecan—breast cancer	0.000248	0.0008	CcSEcCtD
Phentolamine—Nervous system disorder—Capecitabine—breast cancer	0.000247	0.000794	CcSEcCtD
Phentolamine—Diarrhoea—Fluorouracil—breast cancer	0.000246	0.000793	CcSEcCtD
Phentolamine—Tachycardia—Capecitabine—breast cancer	0.000245	0.00079	CcSEcCtD
Phentolamine—Cardiac disorder—Methotrexate—breast cancer	0.000245	0.000787	CcSEcCtD
Phentolamine—Hypotension—Docetaxel—breast cancer	0.000243	0.000781	CcSEcCtD
Phentolamine—Abdominal pain—Paclitaxel—breast cancer	0.000242	0.00078	CcSEcCtD
Phentolamine—Angiopathy—Methotrexate—breast cancer	0.000239	0.00077	CcSEcCtD
Phentolamine—Vomiting—Mitoxantrone—breast cancer	0.000239	0.000769	CcSEcCtD
Phentolamine—Vomiting—Irinotecan—breast cancer	0.000239	0.000769	CcSEcCtD
Phentolamine—Dizziness—Fluorouracil—breast cancer	0.000238	0.000766	CcSEcCtD
Phentolamine—Mediastinal disorder—Methotrexate—breast cancer	0.000238	0.000764	CcSEcCtD
Phentolamine—Headache—Mitoxantrone—breast cancer	0.000235	0.000758	CcSEcCtD
Phentolamine—Headache—Irinotecan—breast cancer	0.000235	0.000758	CcSEcCtD
Phentolamine—Hypotension—Capecitabine—breast cancer	0.000235	0.000756	CcSEcCtD
Phentolamine—Paraesthesia—Docetaxel—breast cancer	0.000233	0.000751	CcSEcCtD
Phentolamine—Vomiting—Gemcitabine—breast cancer	0.000233	0.000749	CcSEcCtD
Phentolamine—Bradycardia—Doxorubicin—breast cancer	0.000232	0.000748	CcSEcCtD
Phentolamine—Headache—Gemcitabine—breast cancer	0.000229	0.000738	CcSEcCtD
Phentolamine—Flushing—Epirubicin—breast cancer	0.000229	0.000737	CcSEcCtD
Phentolamine—Cardiac disorder—Epirubicin—breast cancer	0.000229	0.000737	CcSEcCtD
Phentolamine—Vomiting—Fluorouracil—breast cancer	0.000229	0.000737	CcSEcCtD
Phentolamine—Paraesthesia—Capecitabine—breast cancer	0.000226	0.000727	CcSEcCtD
Phentolamine—Headache—Fluorouracil—breast cancer	0.000225	0.000726	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Docetaxel—breast cancer	0.000224	0.000722	CcSEcCtD
Phentolamine—Angiopathy—Epirubicin—breast cancer	0.000224	0.00072	CcSEcCtD
Phentolamine—Nausea—Irinotecan—breast cancer	0.000223	0.000718	CcSEcCtD
Phentolamine—Nausea—Mitoxantrone—breast cancer	0.000223	0.000718	CcSEcCtD
Phentolamine—Mediastinal disorder—Epirubicin—breast cancer	0.000222	0.000715	CcSEcCtD
Phentolamine—Pain—Docetaxel—breast cancer	0.000222	0.000715	CcSEcCtD
Phentolamine—Arrhythmia—Epirubicin—breast cancer	0.00022	0.000709	CcSEcCtD
Phentolamine—Asthenia—Paclitaxel—breast cancer	0.00022	0.000708	CcSEcCtD
Phentolamine—Nausea—Gemcitabine—breast cancer	0.000217	0.0007	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Capecitabine—breast cancer	0.000217	0.000699	CcSEcCtD
Phentolamine—Pruritus—Paclitaxel—breast cancer	0.000217	0.000698	CcSEcCtD
Phentolamine—Pain—Capecitabine—breast cancer	0.000215	0.000692	CcSEcCtD
Phentolamine—Nausea—Fluorouracil—breast cancer	0.000214	0.000688	CcSEcCtD
Phentolamine—Gastrointestinal pain—Docetaxel—breast cancer	0.000212	0.000684	CcSEcCtD
Phentolamine—Flushing—Doxorubicin—breast cancer	0.000212	0.000682	CcSEcCtD
Phentolamine—Cardiac disorder—Doxorubicin—breast cancer	0.000212	0.000682	CcSEcCtD
Phentolamine—Diarrhoea—Paclitaxel—breast cancer	0.00021	0.000675	CcSEcCtD
Phentolamine—Angiopathy—Doxorubicin—breast cancer	0.000207	0.000666	CcSEcCtD
Phentolamine—Gastrointestinal pain—Capecitabine—breast cancer	0.000206	0.000662	CcSEcCtD
Phentolamine—Mediastinal disorder—Doxorubicin—breast cancer	0.000206	0.000662	CcSEcCtD
Phentolamine—Abdominal pain—Docetaxel—breast cancer	0.000205	0.000661	CcSEcCtD
Phentolamine—Arrhythmia—Doxorubicin—breast cancer	0.000204	0.000656	CcSEcCtD
Phentolamine—Dizziness—Paclitaxel—breast cancer	0.000203	0.000652	CcSEcCtD
Phentolamine—Abdominal pain—Capecitabine—breast cancer	0.000199	0.00064	CcSEcCtD
Phentolamine—Chest pain—Methotrexate—breast cancer	0.000195	0.000629	CcSEcCtD
Phentolamine—Vomiting—Paclitaxel—breast cancer	0.000195	0.000627	CcSEcCtD
Phentolamine—Headache—Paclitaxel—breast cancer	0.000192	0.000618	CcSEcCtD
Phentolamine—Asthenia—Docetaxel—breast cancer	0.000186	0.0006	CcSEcCtD
Phentolamine—Hypertension—Epirubicin—breast cancer	0.000185	0.000597	CcSEcCtD
Phentolamine—Pruritus—Docetaxel—breast cancer	0.000184	0.000592	CcSEcCtD
Phentolamine—Nervous system disorder—Methotrexate—breast cancer	0.000184	0.000591	CcSEcCtD
Phentolamine—Chest pain—Epirubicin—breast cancer	0.000183	0.000588	CcSEcCtD
Phentolamine—Nausea—Paclitaxel—breast cancer	0.000182	0.000586	CcSEcCtD
Phentolamine—Asthenia—Capecitabine—breast cancer	0.00018	0.000581	CcSEcCtD
Phentolamine—Pruritus—Capecitabine—breast cancer	0.000178	0.000573	CcSEcCtD
Phentolamine—Diarrhoea—Docetaxel—breast cancer	0.000178	0.000572	CcSEcCtD
Phentolamine—Hypotension—Methotrexate—breast cancer	0.000175	0.000563	CcSEcCtD
Phentolamine—Diarrhoea—Capecitabine—breast cancer	0.000172	0.000554	CcSEcCtD
Phentolamine—Nervous system disorder—Epirubicin—breast cancer	0.000172	0.000553	CcSEcCtD
Phentolamine—Dizziness—Docetaxel—breast cancer	0.000172	0.000553	CcSEcCtD
Phentolamine—Hypertension—Doxorubicin—breast cancer	0.000172	0.000552	CcSEcCtD
Phentolamine—Tachycardia—Epirubicin—breast cancer	0.000171	0.00055	CcSEcCtD
Phentolamine—Chest pain—Doxorubicin—breast cancer	0.000169	0.000544	CcSEcCtD
Phentolamine—Paraesthesia—Methotrexate—breast cancer	0.000168	0.000541	CcSEcCtD
Phentolamine—Dizziness—Capecitabine—breast cancer	0.000166	0.000535	CcSEcCtD
Phentolamine—Vomiting—Docetaxel—breast cancer	0.000165	0.000532	CcSEcCtD
Phentolamine—Hypotension—Epirubicin—breast cancer	0.000164	0.000527	CcSEcCtD
Phentolamine—Headache—Docetaxel—breast cancer	0.000163	0.000524	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Methotrexate—breast cancer	0.000162	0.00052	CcSEcCtD
Phentolamine—Pain—Methotrexate—breast cancer	0.00016	0.000515	CcSEcCtD
Phentolamine—Vomiting—Capecitabine—breast cancer	0.00016	0.000515	CcSEcCtD
Phentolamine—Nervous system disorder—Doxorubicin—breast cancer	0.000159	0.000512	CcSEcCtD
Phentolamine—Tachycardia—Doxorubicin—breast cancer	0.000158	0.000509	CcSEcCtD
Phentolamine—Headache—Capecitabine—breast cancer	0.000158	0.000507	CcSEcCtD
Phentolamine—Paraesthesia—Epirubicin—breast cancer	0.000157	0.000506	CcSEcCtD
Phentolamine—Nausea—Docetaxel—breast cancer	0.000154	0.000497	CcSEcCtD
Phentolamine—Gastrointestinal pain—Methotrexate—breast cancer	0.000153	0.000493	CcSEcCtD
Phentolamine—Hypotension—Doxorubicin—breast cancer	0.000151	0.000488	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Epirubicin—breast cancer	0.000151	0.000487	CcSEcCtD
Phentolamine—Pain—Epirubicin—breast cancer	0.00015	0.000482	CcSEcCtD
Phentolamine—Nausea—Capecitabine—breast cancer	0.000149	0.000481	CcSEcCtD
Phentolamine—Abdominal pain—Methotrexate—breast cancer	0.000148	0.000476	CcSEcCtD
Phentolamine—Paraesthesia—Doxorubicin—breast cancer	0.000146	0.000469	CcSEcCtD
Phentolamine—Gastrointestinal pain—Epirubicin—breast cancer	0.000143	0.000461	CcSEcCtD
Phentolamine—Gastrointestinal disorder—Doxorubicin—breast cancer	0.00014	0.000451	CcSEcCtD
Phentolamine—Pain—Doxorubicin—breast cancer	0.000139	0.000446	CcSEcCtD
Phentolamine—Abdominal pain—Epirubicin—breast cancer	0.000139	0.000446	CcSEcCtD
Phentolamine—Asthenia—Methotrexate—breast cancer	0.000134	0.000432	CcSEcCtD
Phentolamine—Gastrointestinal pain—Doxorubicin—breast cancer	0.000133	0.000427	CcSEcCtD
Phentolamine—Pruritus—Methotrexate—breast cancer	0.000132	0.000426	CcSEcCtD
Phentolamine—Abdominal pain—Doxorubicin—breast cancer	0.000128	0.000413	CcSEcCtD
Phentolamine—Diarrhoea—Methotrexate—breast cancer	0.000128	0.000412	CcSEcCtD
Phentolamine—Asthenia—Epirubicin—breast cancer	0.000126	0.000405	CcSEcCtD
Phentolamine—Pruritus—Epirubicin—breast cancer	0.000124	0.000399	CcSEcCtD
Phentolamine—Dizziness—Methotrexate—breast cancer	0.000124	0.000399	CcSEcCtD
Phentolamine—Diarrhoea—Epirubicin—breast cancer	0.00012	0.000386	CcSEcCtD
Phentolamine—Vomiting—Methotrexate—breast cancer	0.000119	0.000383	CcSEcCtD
Phentolamine—Headache—Methotrexate—breast cancer	0.000117	0.000378	CcSEcCtD
Phentolamine—Asthenia—Doxorubicin—breast cancer	0.000116	0.000374	CcSEcCtD
Phentolamine—Dizziness—Epirubicin—breast cancer	0.000116	0.000373	CcSEcCtD
Phentolamine—Pruritus—Doxorubicin—breast cancer	0.000115	0.000369	CcSEcCtD
Phentolamine—Vomiting—Epirubicin—breast cancer	0.000111	0.000359	CcSEcCtD
Phentolamine—Nausea—Methotrexate—breast cancer	0.000111	0.000358	CcSEcCtD
Phentolamine—Diarrhoea—Doxorubicin—breast cancer	0.000111	0.000357	CcSEcCtD
Phentolamine—Headache—Epirubicin—breast cancer	0.00011	0.000353	CcSEcCtD
Phentolamine—Dizziness—Doxorubicin—breast cancer	0.000107	0.000345	CcSEcCtD
Phentolamine—Nausea—Epirubicin—breast cancer	0.000104	0.000335	CcSEcCtD
Phentolamine—Vomiting—Doxorubicin—breast cancer	0.000103	0.000332	CcSEcCtD
Phentolamine—Headache—Doxorubicin—breast cancer	0.000102	0.000327	CcSEcCtD
Phentolamine—Nausea—Doxorubicin—breast cancer	9.63e-05	0.00031	CcSEcCtD
Phentolamine—ADRA2C—Signaling Pathways—SERPINE1—breast cancer	7.76e-06	8.14e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—HRAS—breast cancer	7.74e-06	8.12e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CD—breast cancer	7.72e-06	8.1e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EGF—breast cancer	7.71e-06	8.09e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—KRAS—breast cancer	7.68e-06	8.05e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ESR1—breast cancer	7.67e-06	8.04e-05	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—PIK3CA—breast cancer	7.65e-06	8.02e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—SERPINE1—breast cancer	7.64e-06	8.01e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CD—breast cancer	7.62e-06	7.99e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CDKN1B—breast cancer	7.61e-06	7.98e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—FN1—breast cancer	7.57e-06	7.94e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—KRAS—breast cancer	7.56e-06	7.93e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—PIK3CA—breast cancer	7.55e-06	7.92e-05	CbGpPWpGaD
Phentolamine—ADRA1D—GPCR downstream signaling—AKT1—breast cancer	7.53e-06	7.89e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MDM2—breast cancer	7.52e-06	7.89e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—ALB—breast cancer	7.52e-06	7.89e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—RAF1—breast cancer	7.5e-06	7.86e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NFKBIA—breast cancer	7.48e-06	7.85e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—MAPK3—breast cancer	7.47e-06	7.83e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—RELA—breast cancer	7.47e-06	7.83e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CASP3—breast cancer	7.46e-06	7.82e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IL2—breast cancer	7.45e-06	7.81e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—ERBB2—breast cancer	7.42e-06	7.78e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NOTCH1—breast cancer	7.41e-06	7.77e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—IL6—breast cancer	7.41e-06	7.77e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—NOS3—breast cancer	7.41e-06	7.77e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—BRAF—breast cancer	7.33e-06	7.69e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PIK3CB—breast cancer	7.32e-06	7.68e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MTOR—breast cancer	7.32e-06	7.68e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—NOS3—breast cancer	7.29e-06	7.64e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CCND1—breast cancer	7.26e-06	7.61e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—KIT—breast cancer	7.25e-06	7.6e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—APC—breast cancer	7.25e-06	7.6e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CG—breast cancer	7.25e-06	7.6e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—JUN—breast cancer	7.24e-06	7.6e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—NOS3—breast cancer	7.2e-06	7.55e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CTNNB1—breast cancer	7.19e-06	7.54e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EGF—breast cancer	7.17e-06	7.51e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IGF1—breast cancer	7.14e-06	7.49e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AKT2—breast cancer	7.14e-06	7.48e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—EGFR—breast cancer	7.11e-06	7.45e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PTEN—breast cancer	7.07e-06	7.41e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—PIK3CA—breast cancer	7.06e-06	7.4e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MMP9—breast cancer	7.05e-06	7.39e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CXCL8—breast cancer	7.04e-06	7.38e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MDM2—breast cancer	7.03e-06	7.37e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—CDKN1A—breast cancer	7.02e-06	7.36e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PTEN—breast cancer	7.01e-06	7.35e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—RAF1—breast cancer	7e-06	7.34e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—HRAS—breast cancer	6.99e-06	7.33e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—RELA—breast cancer	6.97e-06	7.31e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—PIK3CA—breast cancer	6.95e-06	7.28e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—MAPK3—breast cancer	6.94e-06	7.28e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—ERBB2—breast cancer	6.93e-06	7.27e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MDM2—breast cancer	6.92e-06	7.25e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—RAF1—breast cancer	6.89e-06	7.23e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CDKN1B—breast cancer	6.87e-06	7.2e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—RELA—breast cancer	6.86e-06	7.2e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CD—breast cancer	6.86e-06	7.19e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MAPK8—breast cancer	6.85e-06	7.19e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MTOR—breast cancer	6.84e-06	7.17e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CB—breast cancer	6.84e-06	7.17e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling by GPCR—AKT1—breast cancer	6.84e-06	7.17e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—ERBB2—breast cancer	6.82e-06	7.15e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—BRAF—breast cancer	6.81e-06	7.14e-05	CbGpPWpGaD
Phentolamine—ADRA2B—GPCR downstream signaling—AKT1—breast cancer	6.8e-06	7.13e-05	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—PIK3CA—breast cancer	6.79e-06	7.12e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SERPINE1—breast cancer	6.78e-06	7.11e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CASP3—breast cancer	6.73e-06	7.06e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MTOR—breast cancer	6.73e-06	7.06e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CB—breast cancer	6.73e-06	7.06e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IL2—breast cancer	6.72e-06	7.05e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—KRAS—breast cancer	6.71e-06	7.04e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—IL6—breast cancer	6.69e-06	7.01e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CB—breast cancer	6.64e-06	6.97e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IGF1—breast cancer	6.64e-06	6.96e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AKT2—breast cancer	6.63e-06	6.95e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—EGFR—breast cancer	6.6e-06	6.92e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PTGS2—breast cancer	6.58e-06	6.9e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CXCL8—breast cancer	6.57e-06	6.89e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CCND1—breast cancer	6.55e-06	6.87e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—JUN—breast cancer	6.54e-06	6.86e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—HRAS—breast cancer	6.53e-06	6.85e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—SRC—breast cancer	6.5e-06	6.81e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CTNNB1—breast cancer	6.49e-06	6.81e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—NOS3—breast cancer	6.48e-06	6.79e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CXCL8—breast cancer	6.47e-06	6.78e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—HRAS—breast cancer	6.43e-06	6.74e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CDKN1B—breast cancer	6.42e-06	6.73e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CD—breast cancer	6.37e-06	6.68e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MMP9—breast cancer	6.36e-06	6.67e-05	CbGpPWpGaD
Phentolamine—ADRA2C—GPCR downstream signaling—AKT1—breast cancer	6.35e-06	6.66e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—CDKN1A—breast cancer	6.34e-06	6.65e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—VEGFA—breast cancer	6.33e-06	6.64e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PTEN—breast cancer	6.33e-06	6.63e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CDKN1B—breast cancer	6.32e-06	6.62e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—PIK3CA—breast cancer	6.31e-06	6.62e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SERPINE1—breast cancer	6.3e-06	6.61e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CASP3—breast cancer	6.29e-06	6.59e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IL2—breast cancer	6.28e-06	6.58e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—STAT3—breast cancer	6.27e-06	6.57e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—IL6—breast cancer	6.25e-06	6.55e-05	CbGpPWpGaD
Phentolamine—ADRA1B—GPCR downstream signaling—AKT1—breast cancer	6.25e-06	6.55e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—KRAS—breast cancer	6.24e-06	6.54e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CASP3—breast cancer	6.19e-06	6.49e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MAPK8—breast cancer	6.19e-06	6.49e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL2—breast cancer	6.18e-06	6.48e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling by GPCR—AKT1—breast cancer	6.17e-06	6.47e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—PIK3CA—breast cancer	6.17e-06	6.47e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—IL6—breast cancer	6.15e-06	6.45e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MDM2—breast cancer	6.14e-06	6.44e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—RAF1—breast cancer	6.12e-06	6.42e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CCND1—breast cancer	6.12e-06	6.42e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—JUN—breast cancer	6.11e-06	6.41e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—RELA—breast cancer	6.1e-06	6.39e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CTNNB1—breast cancer	6.06e-06	6.36e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—ERBB2—breast cancer	6.06e-06	6.35e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CCND1—breast cancer	6.03e-06	6.32e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—NOS3—breast cancer	6.02e-06	6.31e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—JUN—breast cancer	6.01e-06	6.3e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MAPK3—breast cancer	5.99e-06	6.28e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CB—breast cancer	5.98e-06	6.27e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MTOR—breast cancer	5.98e-06	6.27e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CTNNB1—breast cancer	5.97e-06	6.26e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MMP9—breast cancer	5.94e-06	6.23e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—CDKN1A—breast cancer	5.92e-06	6.21e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PTEN—breast cancer	5.91e-06	6.2e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—SRC—breast cancer	5.87e-06	6.15e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MMP9—breast cancer	5.85e-06	6.13e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—CDKN1A—breast cancer	5.83e-06	6.11e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—MYC—breast cancer	5.82e-06	6.11e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PTEN—breast cancer	5.82e-06	6.1e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—TGFB1—breast cancer	5.81e-06	6.09e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MAPK8—breast cancer	5.78e-06	6.06e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling by GPCR—AKT1—breast cancer	5.76e-06	6.04e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CXCL8—breast cancer	5.74e-06	6.02e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PTEN—breast cancer	5.74e-06	6.02e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	5.73e-06	6.01e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—VEGFA—breast cancer	5.71e-06	5.99e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MDM2—breast cancer	5.71e-06	5.99e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—HRAS—breast cancer	5.71e-06	5.98e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—EGFR—breast cancer	5.7e-06	5.97e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MAPK8—breast cancer	5.69e-06	5.97e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—RAF1—breast cancer	5.69e-06	5.97e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling by GPCR—AKT1—breast cancer	5.67e-06	5.95e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—RELA—breast cancer	5.66e-06	5.94e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—STAT3—breast cancer	5.66e-06	5.93e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—ERBB2—breast cancer	5.63e-06	5.9e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	5.61e-06	5.88e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	5.55e-06	5.82e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MTOR—breast cancer	5.55e-06	5.82e-05	CbGpPWpGaD
Phentolamine—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	5.55e-06	5.82e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CASP3—breast cancer	5.5e-06	5.77e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL2—breast cancer	5.49e-06	5.76e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—SRC—breast cancer	5.48e-06	5.75e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—IL6—breast cancer	5.46e-06	5.73e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MAPK3—breast cancer	5.41e-06	5.67e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—SRC—breast cancer	5.39e-06	5.66e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—KRAS—breast cancer	5.38e-06	5.64e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CCND1—breast cancer	5.35e-06	5.61e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—JUN—breast cancer	5.34e-06	5.6e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CXCL8—breast cancer	5.34e-06	5.6e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—VEGFA—breast cancer	5.34e-06	5.6e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—HRAS—breast cancer	5.3e-06	5.56e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	5.3e-06	5.56e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—STAT3—breast cancer	5.28e-06	5.54e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—MYC—breast cancer	5.26e-06	5.51e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—VEGFA—breast cancer	5.25e-06	5.51e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—TGFB1—breast cancer	5.24e-06	5.5e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	5.21e-06	5.47e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—STAT3—breast cancer	5.2e-06	5.45e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MMP9—breast cancer	5.2e-06	5.45e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	5.18e-06	5.43e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PTEN—breast cancer	5.17e-06	5.42e-05	CbGpPWpGaD
Phentolamine—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	5.16e-06	5.41e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—EGFR—breast cancer	5.14e-06	5.39e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CASP3—breast cancer	5.11e-06	5.36e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL2—breast cancer	5.1e-06	5.35e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—IL6—breast cancer	5.08e-06	5.32e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MAPK8—breast cancer	5.05e-06	5.3e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MAPK3—breast cancer	5.05e-06	5.29e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling by GPCR—AKT1—breast cancer	5.04e-06	5.28e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—PIK3CA—breast cancer	4.99e-06	5.23e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CCND1—breast cancer	4.97e-06	5.21e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MAPK3—breast cancer	4.97e-06	5.21e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—JUN—breast cancer	4.96e-06	5.2e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—PIK3CA—breast cancer	4.94e-06	5.18e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	4.92e-06	5.16e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—MYC—breast cancer	4.91e-06	5.15e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TGFB1—breast cancer	4.9e-06	5.14e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—KRAS—breast cancer	4.86e-06	5.09e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—MYC—breast cancer	4.83e-06	5.07e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MMP9—breast cancer	4.83e-06	5.06e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TGFB1—breast cancer	4.82e-06	5.06e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	4.81e-06	5.04e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—EGFR—breast cancer	4.8e-06	5.04e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PTEN—breast cancer	4.8e-06	5.03e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—SRC—breast cancer	4.79e-06	5.02e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—TP53—breast cancer	4.78e-06	5.01e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—EGFR—breast cancer	4.73e-06	4.96e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MAPK8—breast cancer	4.7e-06	4.92e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling by GPCR—AKT1—breast cancer	4.68e-06	4.91e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—VEGFA—breast cancer	4.67e-06	4.89e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—STAT3—breast cancer	4.62e-06	4.84e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—HRAS—breast cancer	4.57e-06	4.8e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—KRAS—breast cancer	4.54e-06	4.76e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—KRAS—breast cancer	4.47e-06	4.68e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	4.46e-06	4.68e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—SRC—breast cancer	4.45e-06	4.67e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MAPK3—breast cancer	4.41e-06	4.63e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—IL6—breast cancer	4.38e-06	4.59e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—VEGFA—breast cancer	4.34e-06	4.55e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—TP53—breast cancer	4.32e-06	4.53e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—MYC—breast cancer	4.29e-06	4.5e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—STAT3—breast cancer	4.29e-06	4.5e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TGFB1—breast cancer	4.28e-06	4.49e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—EGFR—breast cancer	4.2e-06	4.4e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	4.17e-06	4.37e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—HRAS—breast cancer	4.13e-06	4.33e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—PIK3CA—breast cancer	4.1e-06	4.3e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MAPK3—breast cancer	4.1e-06	4.3e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Metabolism—AKT1—breast cancer	4.07e-06	4.27e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—PIK3CA—breast cancer	4.05e-06	4.25e-05	CbGpPWpGaD
Phentolamine—ADRA1D—Signaling Pathways—AKT1—breast cancer	4.04e-06	4.23e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—TP53—breast cancer	4.03e-06	4.23e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—MYC—breast cancer	3.99e-06	4.18e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TGFB1—breast cancer	3.98e-06	4.17e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—TP53—breast cancer	3.97e-06	4.16e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—KRAS—breast cancer	3.97e-06	4.16e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—IL6—breast cancer	3.95e-06	4.14e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—EGFR—breast cancer	3.9e-06	4.09e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—HRAS—breast cancer	3.86e-06	4.04e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—HRAS—breast cancer	3.8e-06	3.98e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—IL6—breast cancer	3.69e-06	3.87e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—KRAS—breast cancer	3.69e-06	3.86e-05	CbGpPWpGaD
Phentolamine—ADRA2B—Signaling Pathways—AKT1—breast cancer	3.65e-06	3.82e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	3.64e-06	3.82e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—IL6—breast cancer	3.63e-06	3.81e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—TP53—breast cancer	3.53e-06	3.7e-05	CbGpPWpGaD
Phentolamine—ADRA2C—Signaling Pathways—AKT1—breast cancer	3.41e-06	3.57e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	3.39e-06	3.55e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—HRAS—breast cancer	3.37e-06	3.54e-05	CbGpPWpGaD
Phentolamine—ADRA1B—Signaling Pathways—AKT1—breast cancer	3.35e-06	3.51e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Metabolism—AKT1—breast cancer	3.31e-06	3.47e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—TP53—breast cancer	3.28e-06	3.43e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—IL6—breast cancer	3.23e-06	3.38e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—HRAS—breast cancer	3.13e-06	3.28e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—IL6—breast cancer	3e-06	3.14e-05	CbGpPWpGaD
Phentolamine—ADRA1A—Signaling Pathways—AKT1—breast cancer	2.98e-06	3.12e-05	CbGpPWpGaD
Phentolamine—ADRA2A—Signaling Pathways—AKT1—breast cancer	2.77e-06	2.9e-05	CbGpPWpGaD
